Emily Field
Stock Analyst at Barclays
(1.08)
# 3,856
Out of 5,182 analysts
16
Total ratings
33.33%
Success rate
-3.56%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Emily Field
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| LLY Eli Lilly and Company | Maintains: Overweight | $1,350 → $1,400 | $993.59 | +40.90% | 2 | May 5, 2026 | |
| PFE Pfizer | Initiates: Underweight | $25 | $26.51 | -5.70% | 1 | Feb 20, 2026 | |
| MRK Merck & Co. | Initiates: Overweight | $140 | $113.83 | +22.99% | 1 | Feb 20, 2026 | |
| GILD Gilead Sciences | Initiates: Equal-Weight | $155 | $134.89 | +14.91% | 1 | Feb 20, 2026 | |
| BMY Bristol-Myers Squibb Company | Initiates: Overweight | $75 | $57.04 | +31.49% | 1 | Feb 20, 2026 | |
| BIIB Biogen | Initiates: Equal-Weight | $185 | $188.97 | -2.10% | 1 | Feb 20, 2026 | |
| AMGN Amgen | Initiates: Equal-Weight | $350 | $332.56 | +5.24% | 1 | Feb 20, 2026 | |
| ABBV AbbVie | Initiates: Overweight | $275 | $205.66 | +33.72% | 1 | Feb 20, 2026 | |
| NVO Novo Nordisk | Downgrades: Equal-Weight | n/a | $46.21 | - | 1 | Jul 30, 2025 | |
| GLPG Galapagos NV | Downgrades: Underweight | n/a | $28.86 | - | 1 | Jan 23, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Equal-Weight | n/a | $51.10 | - | 4 | Nov 5, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Overweight | n/a | $807.68 | - | 1 | Oct 19, 2021 |
Eli Lilly and Company
May 5, 2026
Maintains: Overweight
Price Target: $1,350 → $1,400
Current: $993.59
Upside: +40.90%
Pfizer
Feb 20, 2026
Initiates: Underweight
Price Target: $25
Current: $26.51
Upside: -5.70%
Merck & Co.
Feb 20, 2026
Initiates: Overweight
Price Target: $140
Current: $113.83
Upside: +22.99%
Gilead Sciences
Feb 20, 2026
Initiates: Equal-Weight
Price Target: $155
Current: $134.89
Upside: +14.91%
Bristol-Myers Squibb Company
Feb 20, 2026
Initiates: Overweight
Price Target: $75
Current: $57.04
Upside: +31.49%
Biogen
Feb 20, 2026
Initiates: Equal-Weight
Price Target: $185
Current: $188.97
Upside: -2.10%
Amgen
Feb 20, 2026
Initiates: Equal-Weight
Price Target: $350
Current: $332.56
Upside: +5.24%
AbbVie
Feb 20, 2026
Initiates: Overweight
Price Target: $275
Current: $205.66
Upside: +33.72%
Novo Nordisk
Jul 30, 2025
Downgrades: Equal-Weight
Price Target: n/a
Current: $46.21
Upside: -
Galapagos NV
Jan 23, 2025
Downgrades: Underweight
Price Target: n/a
Current: $28.86
Upside: -
Nov 5, 2021
Upgrades: Equal-Weight
Price Target: n/a
Current: $51.10
Upside: -
Oct 19, 2021
Upgrades: Overweight
Price Target: n/a
Current: $807.68
Upside: -